Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 20, 2009

CV Therapeutics Says Astellas’ $1B Offer Is Insufficient

  • CV Therapeutics has rejected Astellas Pharma’s $1 billion unsolicited proposal. The board previously rejected the same proposal in November 2008, when Astellas approached the company privately with an offer of $16 per share.

    As was expected, CV Therapeutics found that Astellas’ bid was below the firm’s true value. The company, which was trading around $11 before Astellas made its offer public, has been valued over $15 ever since but hasn’t quite reached Astellas’ $16 mark. Nonetheless, the company reiterates that 2008 was a good year on various fronts and it expects 2009 to be even better.

    The company is referring to the U.S. approval of Lexiscan in April for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging, the EMEA approval in July of Ranexa for chronic angina, and the label-extension received from the FDA for Ranexa in February allowing its use as a first-line therapy.

    Simultaneously, the company entered two transactions for these products, which brought in $255 million in cash. Menarini paid $70 million for European rights to Ranexa, and TPG-Axon Capital paid $185 million for 50% of the company’s royalties on Lexiscan in North America. CV Therapeutics earned another $10 million from TPG with the launch of Lexiscan.



    To comment on this story, go to BLOGbiotech.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »